16/09/2025 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
The Ministry of Health’s Drug Advisory Committee has recommended:
- Aflibercept 2 mg/0.05 mL pr...
16/09/2025 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
The Ministry of Health’s Drug Advisory Committee has recommended:
- Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and
- Faricimab 6 mg/0.05 mL vial
for treating adults with visual impairment due to:
- diabetic macular oedema; and
- neovascular (wet) age-related macular degeneration.
Funding status
RAflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025.
RFaricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024.
NRMAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration.
16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion
The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL pref...
16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion
The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL prefilled syringe and vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion.
The Ministry of Health’s Drug Advisory Committee has not recommended faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion, due to the unacceptable pricing proposal from the company.
Funding status
RAflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
NRMAF assistance does not apply to faricimab, and other formulation(s) or strengths(s) of aflibercept for the abovementioned indication.
12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
NRThe Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizuma...
12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
NRThe Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizumab reference biologic (Avastin) or ramucirumab for subsidy for treating metastatic colorectal cancer.
NRBevacizumab (Avastin) has not been recommended in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.
NRAflibercept has not been recommended due to low clinical need and unfavourable cost effectiveness compared with Mvasi.
NRRamucirumab has not been recommended following a request from the manufacturer to not consider it for subsidy.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.